Cannara Biotech (LOVE) Stock Overview
Engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LOVE Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cannara Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.03 |
| 52 Week High | CA$2.07 |
| 52 Week Low | CA$1.55 |
| Beta | 0.36 |
| 1 Month Change | 2.01% |
| 3 Month Change | 26.88% |
| 1 Year Change | 15.34% |
| 3 Year Change | 109.28% |
| 5 Year Change | 35.33% |
| Change since IPO | -33.44% |
Recent News & Updates
New Narrative • Aug 01
Expanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis Upside
Catalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products across Canada, supported by a vertically integrated cultivation and processing platform. What are the underlying business or industry changes driving this perspective?Analysis Article • Jul 23
Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) Shareholders
The subdued market reaction suggests that Cannara Biotech Inc.'s ( TSE:LOVE ) recent earnings didn't contain any...
New Narrative • Jul 18
Capacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer Relief
Catalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products in Canada through its Tribal, Nugz and Orchid brands, supported by vertically integrated cultivation and processing facilities. What are the underlying business or industry changes driving this perspective?Recent updates
New Narrative • Aug 01
Expanded Valleyfield Capacity And Blue River Partnership Will Anchor Long-Term Cannabis Upside
Catalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products across Canada, supported by a vertically integrated cultivation and processing platform. What are the underlying business or industry changes driving this perspective?Analysis Article • Jul 23
Earnings Troubles May Signal Larger Issues for Cannara Biotech (TSE:LOVE) Shareholders
The subdued market reaction suggests that Cannara Biotech Inc.'s ( TSE:LOVE ) recent earnings didn't contain any...New Narrative • Jul 18
Capacity Expansion And Rising SG&A Will Test Margins Yet Future Exports May Offer Relief
Catalysts About Cannara Biotech Cannara Biotech produces and sells cannabis products in Canada through its Tribal, Nugz and Orchid brands, supported by vertically integrated cultivation and processing facilities. What are the underlying business or industry changes driving this perspective?
New Narrative • Apr 25
Expanded Capacity And EU Export Optionality Will Support Long Term Premium Cannabis Demand
Catalysts About Cannara Biotech Cannara Biotech is a vertically integrated Canadian cannabis producer focused on premium branded products at competitive price points. What are the underlying business or industry changes driving this perspective?Analysis Article • Dec 01
Cannara Biotech (CVE:LOVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Cannara Biotech Inc.'s ( CVE:LOVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...Analysis Article • Jul 05
Investors Still Aren't Entirely Convinced By Cannara Biotech Inc.'s (CVE:LOVE) Earnings Despite 27% Price Jump
Cannara Biotech Inc. ( CVE:LOVE ) shareholders have had their patience rewarded with a 27% share price jump in the last...Analysis Article • May 09
A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 26% Share Price Climb
Cannara Biotech Inc. ( CVE:LOVE ) shares have had a really impressive month, gaining 26% after a shaky period...Analysis Article • May 07
There May Be Underlying Issues With The Quality Of Cannara Biotech's (CVE:LOVE) Earnings
Cannara Biotech Inc.'s ( CVE:LOVE ) robust earnings report didn't manage to move the market for its stock. We did some...Analysis Article • Apr 07
We Like These Underlying Return On Capital Trends At Cannara Biotech (CVE:LOVE)
There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...Analysis Article • Jan 29
A Piece Of The Puzzle Missing From Cannara Biotech Inc.'s (CVE:LOVE) 40% Share Price Climb
Cannara Biotech Inc. ( CVE:LOVE ) shareholders have had their patience rewarded with a 40% share price jump in the last...Analysis Article • Jan 03
Returns At Cannara Biotech (CVE:LOVE) Are On The Way Up
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analysis Article • Nov 26
Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
When close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 15x, you may consider...Analysis Article • Oct 29
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Aug 22
Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Those holding Cannara Biotech Inc. ( CVE:LOVE ) shares would be relieved that the share price has rebounded 33% in the...Analysis Article • Aug 21
Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analysis Article • Jul 14
Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 09
Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
Cannara Biotech Inc.'s ( CVE:LOVE ) price-to-earnings (or "P/E") ratio of 10.7x might make it look like a buy right now...Analysis Article • Feb 28
Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Jan 24
Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
It's not a stretch to say that Cannara Biotech Inc.'s ( CVE:LOVE ) price-to-earnings (or "P/E") ratio of 11.8x right...Analysis Article • Dec 18
Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Cannara Biotech Inc.'s ( CVE:LOVE ) stock was strong after they recently reported robust earnings. We did some analysis...Analysis Article • Jul 29
Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Apr 10
Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
When close to half the companies in Canada have price-to-earnings ratios (or "P/E's") below 10x, you may consider...Analysis Article • Jan 26
Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jan 27
Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Even though Cannara Biotech Inc. ( CVE:LOVE ) posted strong earnings recently, the stock hasn't reacted in a large way...Analysis Article • Dec 10
Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 16
Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jan 22
Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Cannara Biotech Inc. ( CSE:LOVE ) shareholders will doubtless be very grateful to see the share price up 81% in the...Analysis Article • Dec 18
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...Shareholder Returns
| LOVE | CA Personal Products | CA Market | |
|---|---|---|---|
| 7D | 1.5% | -0.1% | 0.2% |
| 1Y | 15.3% | 17.9% | 20.9% |
Return vs Industry: LOVE underperformed the Canadian Personal Products industry which returned 17.9% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 20.9% over the past year.
Price Volatility
| LOVE volatility | |
|---|---|
| LOVE Average Weekly Movement | 4.5% |
| Personal Products Industry Average Movement | 8.7% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 16.0% |
| 10% least volatile stocks in CA Market | 3.6% |
Stable Share Price: LOVE has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: LOVE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 452 | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name.
Cannara Biotech Inc. Fundamentals Summary
| LOVE fundamental statistics | |
|---|---|
| Market cap | CA$197.56m |
| Earnings (TTM) | CA$10.86m |
| Revenue (TTM) | CA$117.33m |
18.5x
P/E Ratio1.7x
P/S RatioIs LOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOVE income statement (TTM) | |
|---|---|
| Revenue | CA$117.33m |
| Cost of Revenue | CA$67.36m |
| Gross Profit | CA$49.97m |
| Other Expenses | CA$39.12m |
| Earnings | CA$10.86m |
Last Reported Earnings
May 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 42.59% |
| Net Profit Margin | 9.25% |
| Debt/Equity Ratio | 29.3% |
How did LOVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 21:58 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/05/31 |
| Annual Earnings | 2025/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cannara Biotech Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nicholas Cortellucci | Atrium Research |
| Neal Gilmer | Haywood Securities Inc. |
| Greg McLeish | Research Capital Corporation |